Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 11,201–11,300 of 12,156

  1. Adverse kidney events with initiation of SGLT2 inhibitors versus DPP4 inhibitors in diabetic people with a history of acute kidney injury
    Yi‐Wei Kao, Tze‐Fan Chao, Yu‐Wen Cheng · 2025 · European Journal of Clinical Investigation
  2. The Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Outcomes in Cancer Patients With Type 2 Diabetes Mellitus: A Systematic Review
    Sara Omer Hamid Zain Elabdin, Mostafa F Mohammed, A el-Sheikh · 2025 · Cureus
  3. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (gliflozins) in diabetes mellitus: mechanisms and therapeutic insights
    Shiva K. Rastogi, Mosab A. Odeh, Pranav K. Rastogi · 2025 · Elsevier eBooks
  4. Targeted Clinician Emails to Promote Reinitiation of Sodium-Glucose Cotransporter 2 Inhibitors after Discontinuation for Remediable Side Effects
    Sarah F. Sanghavi, Neha Deval, Ethan Nguyen · 2025 · Clinical Journal of the American Society of Nephrology
  5. Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age
    Kazuhiro Yamamoto, Yusuke Naito, Sakurako Watanabe · 2025 · Expert Opinion on Drug Safety
  6. Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes
    Fu‐Shun Yen, James Cheng-Chung Wei, Yuhan Huang, Pei-Yun Li, Fuu‐Jen Tsai, Chih-Cheng Hsu, Chii‐Min Hwu · 2025 · Diabetes Research and Clinical Practice
  7. Empleo de gliflozinas en pacientes con insuficiencia cardíaca en Atención Primaria. Estudio retrospectivo de su uso en vida real
    Sara Vargas Lobé, Almudena Criado Camargo, Pablo Jerez Fernández, S. Hämäläinen, Juan Antonio López-Rodríguez, María Eloisa Rogero Blanco · 2025 · Revista Clínica de Medicina de Familia
  8. SGLT2i, ARNi and Diuretic Use in Patients with Heart Failure Among the Preserved and Reduced Ejection Fraction: A Retrospective Observational Study
    Mohammad Saabiq Samad, Roopa Satyanarayan Basutkar, Basavaraj Utagi, Anjusha Alex · 2025 · Research Square
  9. Prévention secondaire chez le coronarien
    Emmanuel Sorbets · 2025 · EMC - Traité de médecine AKOS
  10. Gliflozins - the nephrologist's point of view
    Petr Táborský · 2025 · Vnitřní lékařství
  11. Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal
    Folkert H. van Bruggen, Hendrika J. Luijendijk · 2025 · Frontiers in Cardiovascular Medicine
  12. Addressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide
    Rajesh Kumar, Sunil Kumar Singh, Shruti Singh, Alok Kumar · 2025 · International Journal of Basic & Clinical Pharmacology
  13. Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
    Svea Stüdemann, Stefan Engeli · 2025 · Diabetes aktuell
  14. Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction – real world outcomes
    Yoav Hammer, Ronen Arbel, Talish Razi, Doron Netzer, Jean Marc Weinstein, Zaza Iakobishvili · 2025 · Research Square
  15. Cardiac arrhythmias and diabetes mellitus: What a clinician needs to know
    M. N. Nadybina, Ушанова Фатима Омариевна, T. Ya. Izmaylova · 2025 · FOCUS Endocrinology
  16. "Cardiogenic diabetes": Known influence, unknown mechanisms
    Tatiana Yu. Demidova, S. V. Panteleeva, Ушанова Фатима Омариевна · 2025 · FOCUS Endocrinology
  17. SGLT2 Inhibitors: Increasing Benefits, Continued Concerns
    Marisa Hernandez-Morgan, Andrew A. Disque, Jacques Prince Neelankavil · 2025 · Journal of Cardiothoracic and Vascular Anesthesia
  18. Effects of Combined SGLT2 Inhibitor and RAAS Blockade ± Thiazide Therapy on Serum Electrolyte Balance in Type 2 Diabetic Patients: A Retrospective Cohort Study
    Sevgi GULSEN KOC, Lütfullah Zahit Koç, Gökhan Köker, Yasin Şahintürk · 2025 · Research Square
  19. Diabetes mellitus and the kidney
    Luigi Gnudi, Rudolf W. Bilous · 2020
  20. Clinical Considerations for Safe Use of SGLT2 Inhibitors
    Jae‐Seung Yun, Eon Ju Jeon · 2025 · Journal of Korean Diabetes
  21. Efficacy of Empagliflozin Versus Placebo in Patients With Recent Acute Myocardial Infarction: A Systematic Review
    Carlos A Umaña Mejia, Jose Ramon Flores Valdes, Dominique Alvarado Corletto, Milton Abraham Trujillo Asturias, Alfredo I Rojo Mendoza, Paulina Razo, Jaqueline Livier Castillo, Diana R Alvarez Flores, Edwin A Garcia-Vasquez, Luis F López Hernández · 2025 · Cureus
  22. Effect of Ozempic on Diabetic Nephropathy: A Case Report
    Jimmy Joseph · 2025 · Cureus
  23. Impact of Diabetes on the Cardiovascular System in Patients at El Idrissi Hospital in Morocco: An Epidemiological Study
    Abdessamad El Hamaoui, Younes Yassine, Hassan Saidi, Mahjoub Aouane · 2025 · Universal Journal of Public Health
  24. Aerobic exercise after PCI in diabetes: a pillar for cardiovascular prevention
    Roberto F.E. Pedretti, Massimo Gustapane, Giuseppe Princi · 2025 · European Journal of Preventive Cardiology
  25. SGLT2-Hemmung bei Patienten mit Diabetes mellitus Typ 1 und CKD
    Maximilian Seidel · 2025 · Die Nephrologie
  26. Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
    Eva Muja, Letizia Giuseppina Floccari, Artan Simaku · 2025 · Italian Journal of Medicine
  27. SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
    Jia Yi Tan, Aravinthan Vignarajah, Yong Hao Yeo · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
  28. Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management
    Abdul Hamid Zargar, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Alan Fernandes Almeida, Abhijit Taraphder, Sandeep Bansal, Sameer Dani, Nilakshi Deka, Sanjay Jain, Onkar C Swami · 2025 · Cureus
  29. Metabolic Syndrome and Its Effects on the Reno-Vascular System
    Nivedha Balaji, Crystal Ayazo, Idopise E. Umana · 2025 · IntechOpen eBooks
  30. Literatur
    2025 · Elsevier eBooks
  31. Tinnitus and the diabetic individual: a review
    Manish Munjal, Shubham Munjal, Vineeta Arora et al. · 2025 · International Journal of Otorhinolaryngology and Head and Neck Surgery
  32. Cost-utility analysis of add-on SGLT2 inhibitors for heart failure with reduced ejection fraction in India
    Akhil Sasidharan, Sajith Kumar S, G Suchitralakshmi, Kavitha Rajsekar, Bhavani Shankara Bagepally · 2025 · Health Policy and Technology
  33. Novel Interventions to Improve Adherence to Guideline-Directed Medical Therapy in Claudicants
    Richard Shi, Nicholas Bulatao, Adam Tanious · 2025 · Journal of Clinical Medicine
  34. Pleiotropic Effects of Renal Disease Management: Role of SGLT2 Inhibitors
    Iván Omar Calderón-Lojero, Rafael Valdez-Ortiz, Katy A. Sanchez-Pozos · 2025 · BENTHAM SCIENCE PUBLISHERS eBooks
  35. Impact of SGLT2 Inhibitors in the Management of Diabetes and Heart Failure Comorbidity: A Review of Current Evidence
    Saheed Ekundayo Sanyaolu, Opeyemi J. Lawal, Ayomide O. Okundare, Omobolanle I. Ogundele · 2025 · Premier Journal of Biomedical Science
  36. Effect of Exenatide on Metabolic and Inflammatory Markers in Diabetic Obese Patients
    Eşref Araç, Mahsun Çağlin · 2025 · DAHUDER Medical Journal
  37. Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
    Mehmet Hakan Uzun, Sebahat Ulusan, Afragül Yönet et al. · 2025 · Frontiers in Cardiovascular Medicine
  38. Population health approach to optimize SGLT-2 prescribing in a veteran cohort
    Jeffrey D. Kravetz, Megan E Crete, Annette Pimenta · 2025 · The American Journal of Medicine
  39. Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
    Tim Hollstein · 2025 · Aktuelle Kardiologie
  40. Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient: a case report
    Ophélie Dirand, Julie Dupont, Emmanuel Weiss · 2025 · International Journal of Emergency Medicine
  41. The synergistic treatment of heart and kidney disease
    Felix Mahfoud, Felix Götzinger, Rafael Kramann, Nikolaus Marx, Vedat Schwenger · 2026 · Deutsches Ärzteblatt international
  42. Novel therapies – IMID Co-morbidities
    Tommy Tsz‐On Lam, Ho So, Lai‐Shan Tam · 2025 · Best Practice & Research Clinical Rheumatology
  43. Impacto de los Inhibidores SGLT-2 sobre la Fracción de Eyección y Eventos Cardiovasculares en Insuficiencia Cardíaca con Diabetes Tipo 2: Revisión Sistemática y Metaanálisis
    Karla Leslie Martínez Hernández, Beatriz Itzel Martínez Fuentes, Kenia Fabiola Navarro Martin · 2025 · Estudios y Perspectivas Revista Científica y Académica
  44. Management of Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease Risk in People With Type 2 Diabetes: Collaborative Care Plans for Primary Care Physicians Using Effective Communication Styles
    Carlos Campos, Aaron King, Eden M Miller, Javier Morales · 2025 · Clinical Diabetes
  45. Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in a Recipient of Concurrent Pancreas-Kidney Transplantation With Type 1 Diabetes Mellitus
    Takahiro Kawaji, Tsukasa Jinno, S Komatsu, Naohide Kuriyama, Tomoyuki Nakamura · 2025 · Cureus
  46. Renal–adipose neural circuit underlies the weight-lowering effects of sodium-glucose co-transporter 2 inhibitors
    Minoru Yasukawa, Shigeru Shibata · 2025 · Hypertension Research
  47. Canagliflozin Inhibits Electrogenic Na+ Transport in Mouse Cortical Collecting Duct Cells
    Andrew J. Nickerson, Wafaa N. Albalawy, Elynna B. Youm, Nicole A Joseph, Kennedy G Szekely, T. Kleyman, O. Weisz, Ossama B. Kashlan · 2025 · Function
  48. Evaluation of Key Safety Outcomes of SGLT2 Inhibitors in the Real World: A Target Trial Emulation Study
    Chieh‐Li Yen, Pei‐Ru Li, Chao‐Yi Wu · 2025 · SSRN Electronic Journal
  49. A study on drug utilization, evaluation and monitoring of adverse drug reactions in the cardiology department of a tertiary care hospital
    B. Tazneem, Mohammed Mateen, Sameer · 2025 · International Journal of Basic & Clinical Pharmacology
  50. Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes
    Luxcia Kugathasan, Nagarjunachary Ragi, Subrata Debnath, Vikas S. Sridhar, Soumya Maity, Tianqing Feng, Esmeralda Treviño, Bruce A. Perkins, David Z.I. Cherney, Kumar Sharma · 2025 · Physiological Reports
  51. External Exposome Factors and Adverse Heart Failure Outcomes in the OneFlorida+ Network: Retrospective Cohort Study
    Wenxi Huang, Stephen E. Kimmel, Mustafa Mohammed Ahmed, Steven M. Smith, Yao An Lee, Lanting Yang, Inmaculada Hernandez, Jiang Bian, Jingchuan Serena Guo · 2025 · JMIR Formative Research
  52. Managing heart failure with reduced ejection fraction (HFrEF)
    K. Melissa Smith Hayes, Nicole R. Dellise · 2025 · The Nurse Practitioner
  53. Exploring the Therapeutic Potential of SGLT-2 Inhibitors in Managing Metabolic Syndrome: A Narrative Review
    Sulthan Al Rashid, Monisha Prasad, Inamul Hasan Madar, Kamalakannan Dhanabalan, Rajkapoor Balasubramanian, Naina Mohamed Pakkir Maideen · 2025 · Current Drug Research Reviews
  54. Fostering interconnected care in heart failure: a call to action for a comprehensive assessment and management of the patient’s journey
    Ignazio Cusmano, Monica Loguercio, Francesca Di Salvo, Stefano Gonella, Marco Ambrosetti, Nuccia Morici · 2025 · Internal and Emergency Medicine
  55. Diabesidad: concepto e implicancias
    Rodolfo Lahsen · 2025 · Revista Médica Clínica Las Condes
  56. Leitliniengerechte Therapie der chronischen Nierenerkrankung
    Lea Weiland · 2025 · Info Diabetologie
  57. Liraglutide-Metformin Combination Therapy in Type 2 Diabetes: A Comprehensive Review of Clinical Efficacy, Safety and Cost-Effectiveness
    Aashish Choudhary, Sanjaikrishna Pakkirisamy Kannan, Kamala Kanta Parhi, Shridhar Jayagopalan · 2025 · International Journal of experimental research and review
  58. SGLT2 inhibitors in type 2 diabetes mellitus: a pharmacist’s guide to optimised care
    Barney Jordaan, Kim Outhoff · 2025 · SA pharmaceutical journal.
  59. Cardiac Autonomic Outcomes Following Canagliflozin Add-On Therapy in Type 2 Diabetes Patients with Inadequate Glycemic Control: A Prospective and Observational Study
    Dipan Saha, Arindam Naskar, Shatavisa Mukherjee · 2025 · Journal of the Practice of Cardiovascular Sciences
  60. Cardiomyopathy in metabolic diseases: Pharmacological strategies
    Marzieh Monemi, Ali Babaeizad, Zahra Sheikh Soleimany Darany, Ramtin Naderian, Farnaz Alibabaei, Maral Hemati, Fatemeh Mahmoudian, Majid Eslami · 2025 · Elsevier eBooks
  61. Metabolic syndrome: Pharmacological strategies and challenges
    Reza Heidari · 2025 · Elsevier eBooks
  62. Das Heart-Team bei Herzinsuffizienz
    Joanna Jozwiak‐Nozdrzykowska, Marcus Sandri, Maja Hanuna, Sotirios Nedios, Alexey Dashkevich · 2025 · Herz
  63. Advances in SGLT2 Inhibitors for Cardiovascular Diseases
    峰莉 员 · 2025 · Advances in Clinical Medicine
  64. Long-Term Cardiorenal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Single-Center Experience
    Adnan Agha, Bachar O. Afandi, Saeed AlKaabi · 2025 · Journal of Clinical Medicine
  65. The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study
    Hüseyin Ali Öztürk, Hilmi Erdem Sümbül · 2025 · Irish Journal of Medical Science (1971 -)
  66. Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness Analyses
    Kah Suan Chong, Chun‐Ting Yang, Chi‐Chuan Wang, Huang‐Tz Ou, Shihchen Kuo · 2025 · PharmacoEconomics
  67. Understanding inflammatory pathways in cardiovascular diseases: A step toward targeted anti-inflammatory therapies
    Syed Muhammad Essa, Abdul Ghaffar, Milica Jovanovic, Abdul Khaliq, Muhammad Imran Usmani · 2025 · Romanian Journal of Cardiology
  68. ASSESSMENT OF EFFECTIVENESS OF SODIUM-GLUCOSE TRANSPORT PROTEIN-2 INHIBITORS IN TYPE-2 DIABETIC PATIENTS IN A TERTIARY CARE HOSPITAL – A LONGITUDINAL PROSPECTIVE STUDY
    VEERENDRA KUMAR, STV RAGHAVAMMA · 2025 · Asian Journal of Pharmaceutical and Clinical Research
  69. Effectiveness and use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease
    Jian-Qing Tian, Yuhao Lin, Zhi-Jun Zhang, Yi-Ting Peng, Jia‐Wen Ye, Zhiyi Wang · 2025 · Frontiers in Endocrinology
  70. Correlation of Glycemic Status with Angiographic Severity of Coronary Artery Disease in Acute Coronary Syndrome
    Varsha Rakshitha Prakash, Mohammed Omar Shariff, Vadagenalli Sathyanarayanarao Prakash · 2025 · Journal of the Association of Physicians of India
  71. Efficacy and Safety of SGLT2 Inhibitors for Preventing Heart Failure in Post-Myocardial Infarction Patients Without Established Heart Failure: A Systematic Review and Meta-Analysis
    Shankar Kumar Biswas, Elangovan Krishnan, Yashasvi Srivastava, MBBS Kaushik Jain, Yashvant Pravinbhai Bodar, MBBS Harkirat Singh, BMedSci Mustafa Abrar Zaman, MBBS Krishna Giri, MBBS Dhiraj Kumar Das, Syed Khaja Ayaanuddin et al. · 2025 · Research Square
  72. Enhancing evidence-based guidelines using trial emulation in electronic health records: Real-world effects of empagliflozin in people with type 2 diabetes
    David K Ryan, Ruth H. Keogh, Elizabeth Williamson, R Thomas Lumbers, Karla Diaz‐Ordaz, Anoop D Shah, Patrick Bidulka · 2025 · medRxiv
  73. Comparative Risk of Glaucoma in Patients Using Sodium-glucose Cotransporter-2 Inhibitors and Metformin: A Multinational Cohort Study
    Ssu‐Yu Pan, Chien‐Hsiang Weng, Shang-Feng Tsai, Yi‐Jing Sheen, Jun‐Fu Lin, Ching‐Heng Lin, I‐Jong Wang, Chien‐Chih Chou · 2025 · American Journal of Ophthalmology
  74. Editorial: Diabetes and cardiovascular complications: synergistic treatment approaches
    Belma Pojskić · 2025 · Frontiers in Clinical Diabetes and Healthcare
  75. Prevención secundaria en el paciente coronario
    Emmanuel Sorbets · 2025 · EMC - Tratado de Medicina
  76. Cardiovascular Toxicity in Diabetes Mellitus: Focus on Diabetogenic and Anti-diabetogenic Agents
    Nina M. Radisavljevic, Slavica Mutavdžin, Dragan M. Djuric · 2025 · Advances in biochemistry in health and disease
  77. A Comparative Analysis of Diabetic Ketoacidosis (DKA) in Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Users Versus Non-users: A Systematic Review
    Sawsan A. A. Altom, Ali Hadi M Alhajri, Hiba Karimeldin Mohamed Ali, Dalia Abdelrhman Mohammed Ahmed, Marwa AbdalGader Rabah Rahma, Tartel Abdelhamed Mohamed Ahmed, Marwa Mohamoud Mohmmed Abd Alatif, RAMSHA AHMED · 2025 · Cureus
  78. Smoking as a Confounding Factor in Environmentally Induced Lifestyle Diseases
    Syed Amaan Ali, Neha Agrawal, Mohammad Atif · 2025 · Springer eBooks
  79. Trends in Alzheimer Disease and Chronic Kidney Disease–Associated Mortality in the United States, 1999–2020: A Multiple-Cause Analysis of CDC WONDER Data
    Muhammad Masroor Ahmed, Umer Bin Shahzad, Ume Aiman, Rayyan Nabi, Manal Nadeem, Muhammad Faisal Saleem, Muhammad Ansab, Dua Batool Zaide, Saeed Ahmed, Muzammil Farhan et al. · 2025 · Research Square
  80. Patient education and monitoring of sodium-glucose co-transporter 2 inhibitors in diabetes
    Maria Pignatelli-Ruiz, Marie Hill · 2025 · Practice Nursing
  81. What should the doctor prescribe—formula diet or antidiabetics? Effectiveness of formula diet-based lifestyle intervention vs. pharmacological antiglycemic therapy on weight loss and HbA1c reduction in type 2 diabetes patients—a systematic review
    Kerstin Kempf, Martin Röhling, Stéphan Martin · 2025 · Frontiers in Endocrinology
  82. MANAGEMENT OF ATHLETES WITH TYPE 2 DIABETES – THERAPEUTIC AND EDUCATIONAL STRATEGIES IN CLINICAL PRACTICE
    Adam Żuczek, Olga Żuczek, Kinga Dyndał, Marcelina Broda, Patrycja Jędrzejewska-Rzezak, Katarzyna Urbańska, Izabela Szczap, Anna Hawryluk, Kamil Marzec, Aleksandra Mokrzycka · 2025 · International Journal of Innovative Technologies in Social Science
  83. Therapeutic approaches in the management of chronic kidney disease: the past, the present, and the future
    Georgia Doumani, Panagiotis Theofilis, Aikaterini Vordoni, Despina Smirloglou, Rigas Kalaitzidis · 2025 · Minerva Medica
  84. Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study
    Joyita Bharati, Nicholas A. Bosch, Ashish Upadhyay · 2026 · BMC Nephrology
  85. SGLT-2 Inhibitors After Acute Coronary Syndrome As Preventive Approach for Heart Failure-Related Complications: A Meta-Analysis
    Daniel Paulino-González, Miguel Angel Pardiño-Vega, Edwin Andrade-Arbaiza, Shirley Xiloj, Karla V Juárez-Aldana, Sandra E Cruz-Hernandez, Luis Manuel Amezcua-Guerra, Daniel Alejandro Navarro-Martínez · 2025 · American Journal of Therapeutics
  86. Quarante ans d’avancées en cardiologie
    Alain Tedgui, Soraya Taleb · 2025 · médecine/sciences
  87. Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers
    Kar Ming Yee, Elton Sagim, Chuei Wuei Leong et al. · 2025 · Clinical Pharmacology in Drug Development
  88. Platelets and Diabetes
    Francesca Santilli, Paola Simeone · 2025 · Springer eBooks
  89. Decoding the coronary paradox of obesity: not all fat is equal!
    Gaetano Santulli, Shivangi Pande, Pasquale Mone, Fahimeh Varzideh · 2025 · IJC Heart & Vasculature
  90. Major adverse cardiovascular events among patients with type 2 diabetes mellitus: A prospective study
    David Martín Enguix, Juan Carlos Aguirre Rodríguez, Abraham Hidalgo Rodríguez, María Guisasola Cárdenas, María Sánchez Cambronero, María Nieves Generoso Torres, Manuel Joaquín Castillo, Francisco J. Amaro‐Gahete · 2025 · Medicina Clínica (English Edition)
  91. Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
    Phyo Than Htoo, Helen Tesfaye, Sebastian Schneeweiß, Deborah J. Wexler, Robert J. Glynn, Elyse DiCesare, Ariel Freedman, Niklas Schmedt, Christina M. Shay, Julie M. Paik et al. · 2025 · Diabetes Obesity and Metabolism
  92. Current status and future development of novel heart failure therapies focusing on cardiac energy: A narrative review
    Koh Ono, Takahiro Horie, Osamu Baba · 2025 · Asian Heart Journal
  93. Recent Advances in RP-HPLC Method Development and Validation for Empagliflozin: A Comprehensive Review
    2025 · Int Jour of Pharmamedix India
  94. New therapeutic strategies for heart failure
    Joseph William Rossano, William J. Dreyer, John L. Jefferies · 2025 · Elsevier eBooks
  95. Increased ketoacidosis from co administration of glucose-lowering drugs and Metformin: a post-marketing report study
    Ruben A Abagyan, Leon Valentin Richter · 2025 · medRxiv
  96. The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records
    Min Ju Kang, Hyun Kyung Lee, Minoh Ko, Ha Young Jang, In-Wha Kim, Jung Mi Oh · 2025 · International Journal of Clinical Pharmacy
  97. Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use
    Raffaele Marfella, Ludovica Vittoria Marfella, Carlo Fumagalli, Luca Rinaldi, Ferdinando Carlo Sasso, Domenico Cozzolino, Francesco Nappo, Ausilia Sellitto, Ciro Pasquale Romano, Caterina Carusone et al. · 2025 · European Heart Journal - Imaging Methods and Practice
  98. Pharmacologic Therapy to Improve Functional and Limb Outcomes
    Aishwarya Raja, Eric Alexander Secemsky · 2025 · Springer eBooks
  99. Risk Factors for Claudication and Management to Modify Them
    Ramprakash Devadoss, Alvaro Alonso · 2025 · Springer eBooks
  100. Heart Failure With Comorbidities
    Yunhao Li, Ming Liang · 2025 · Cardiology Discovery